Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44056   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-005339-15
    Sponsor's Protocol Code Number:CAIN457A3302
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-02-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-005339-15
    A.3Full title of the trial
    Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment,
    comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c.
    Ottimizzazione della terapia di mantenimento a lungo termine di una cute esente da lesioni in pazienti con psoriasi a placche cronica da moderata a severa: studio
    multicentrico, randomizzato, comparativo, in aperto, con
    valutazione del PASI in cieco, della durata di 52 settimane per determinare l’efficacia, la sicurezza e la tollerabilità del secukinumab 300 mg s.c.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy, safety and tolerability assessment of secukinumab 300 mg s.c. optimization in patients with moderate to severe chronic plaque psoriasis.
    Ottomizzazione della valutazione dell'efficacia, della sicurezza e della tollerabilità di secukinumab 300 mg s.c. in pazienti con psoriasi a placche cronica da moderata a severa.
    A.3.2Name or abbreviated title of the trial where available
    OPTIMISE
    OPTIMISE
    A.4.1Sponsor's protocol code numberCAIN457A3302
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNOVARTIS FARMA S.P.A.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma Services AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNOVARTIS FARMA S.p.A.
    B.5.2Functional name of contact pointDrug Regulatory Affairs
    B.5.3 Address:
    B.5.3.1Street AddressLargo U. Boccioni, 1
    B.5.3.2Town/ cityOriggio (VA)
    B.5.3.3Post code21040
    B.5.3.4CountryItaly
    B.5.4Telephone number00390296541
    B.5.5Fax number0039029659066
    B.5.6E-mailinfo.studiclinici@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS EUROPHARM LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSecukinumab
    D.3.9.1CAS number 1229022-83-6
    D.3.9.2Current sponsor codeAIN457
    D.3.9.3Other descriptive nameSecukinumab
    D.3.9.4EV Substance CodeSUB33242
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Plaque Psoriasis
    Psoriasi a placche
    E.1.1.1Medical condition in easily understood language
    Psoriasis looks like red, raised scaly areas of the skin
    Psoriasi con aree di cute ispessita, arrossata e ricoperta di squame
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10050576
    E.1.2Term Psoriasis vulgaris
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.
    L’obiettivo primario è di dimostrare, nel gruppo di pazienti che ottengono una risposta PASI 90 alla Settimana 24, che il trattamento con secukinumab
    300 mg s.c. ogni 6 settimane non è inferiore al trattamento con secukinumab 300 mg s.c. ogni 4 settimane rispetto al mantenimento di un tasso di risposta PASI 90 alla Settimana 52.
    E.2.2Secondary objectives of the trial
    To demonstrate in the patient pool of PASI 75 responders who do not reach a PASI 90 response at Week 24 that secukinumab 300 mg s.c. administered at a shorter dosing interval is superior to secukinumab 300 mg s.c. administered every 4 weeks at Week 52 based on the PASI 90 response rate.
    Evaluate the proportion of PASI 50, PASI 75, PASI 100 and Novartis Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 responder rates at Week 52.
    Evaluate the course of mean PASI over time from Week 24 to Week 52.
    Evaluate the effect of different maintenance treatment frequencies on patient reported outcomes (PROs): Dermatology Life Quality Index (DLQI©), EuroQOL 5-Dimension Health Questionnaire (EQ-5D©), Work Productivity and Activity Impairment Questionnaire-Psoriasis (WPAIPSO), and the patient's assessment of pain, itching and scaling.
    - Dimostrare, nel gruppo di pazienti che ottengono una risposta PASI 75 ma che non raggiungono una risposta PASI 90 alla Settimana 24, che secukinumab 300 mg s.c. somministrato ogni 2 settimane è superiore a secukinumab 300 mg s.c. somministrato ogni 4
    settimane alla Settimana 52 in base al tasso di risposta PASI 90.
    - Valutare la proporzione dei tassi di risposta PASI 50, PASI 75, PASI 100 e IGA mod 2011 0/1 alla Settimana 52
    - Valutare l’andamento medio dell’indice PASI nel tempo dalla Settimana 24 alla Settimana 52
    - Valutare l’effetto di diverse frequenze di somministrazione del trattamento di mantenimento sugli esiti riportati dai pazienti (PRO): (DLQI®), (EQ-5D®), (WPAIPSO), e la valuvalutazione da parte del paziente del dolore, del prurito e della desquamazione.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Chronic plaque-type psoriasis diagnosed for at least 6 months prior to Screening and candidate for systemic therapy.
    2. Moderate to severe psoriasis at Baseline as evidenced by:
    • PASI ≥ 10 and
    • IGA mod 2011 score of 3 or higher (based on a scale of 0 to 4) and
    • BSA affected by plaque-type psoriasis of ≥ 10%.
    1. Uomini o donne di almeno 18 anni di età al momento dello screening.
    2. Pazienti affetti da psoriasi a placche cronica diagnosticata almeno 6 mesi prima dello screening e candidati a terapia sistemica.
    3. Psoriasi da moderata a severa, come evidenziato da:
    · PASI ≥10 e
    · Punteggio IGA mod 2011 di 3 o superiore (in base ad una scala da 0 a 4) e
    · BSA colpita da psoriasi a placche ≥10%.
    4. Pazienti in grado di comprendere e di comunicare con lo sperimentatore, e in grado di aderire alle richieste dello studio e che hanno fornito un consenso informato scritto firmato e datato prima dell’effettuazione di qualsiasi attività correlata allo studio.
    E.4Principal exclusion criteria
    1. History of exposure to any biologic drug taken for the treatment of chronic plaque psoriasis or any other indication including but not limited to anti-tumor necrosis factor (TNF) alpha, anti-interleukin (IL)12/23, or any anti-IL-17A or IL-17A receptor (IL 17AR) antibody.
    2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
    3. Forms of psoriasis other than chronic plaque-type (eg, pustular, erythrodermic and guttate psoriasis).
    4. Drug-induced psoriasis (ie, new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).
    5. Ongoing use of prohibited psoriasis treatments (eg, topical or systemic corticosteroids, ultraviolet (UV) therapy).
    6. Ongoing use of other non-psoriasis prohibited treatments. Washout periods detailed in the protocol have to be adhered to. All other prior non-psoriasis concomitant treatments must be at a stable dose as detailed in the protocol before initiation of study
    drug.
    7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL).
    8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study drug and for
    16 weeks after stopping study drug.
    9. Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy.
    10. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac,
    infectious or gastrointestinal conditions) which, in the opinion of the Investigator, significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an
    immunomodulatory therapy.
    Other protocol-defined exclusion criteria may apply.
    1. Anamnesi di esposizione a qualsiasi farmaco biologico assunto per il trattamento della psoriasi a placche cronica o per qualsiasi altra indicazione compresi, ma non limitati a, fattore di necrosi anti-tumorale (anti-tumor necrosi factor – TNF) alfa, anti-interleuchina (IL)12/23, o anticorpi anti-IL-17A o anti - recettore di IL-17/A (IL-17AR).
    2. Anamnesi di ipersensibilità ad uno qualsiasi dei trattamenti in studio o a farmaci di classi chimiche simili.
    3.Forme di psoriasi diverse dalla psoriasi cronica a placche (ad es. psoriasi pustolosa, etritrodermica e guttata).
    4. Psoriasi farmaco-indotta (ovvero, insorgenza o attuale esacerbazione da beta-bloccanti, inibitori del canale del calcio o litio).
    5.Attuale uso di trattamenti proibiti per la psoriasi (ad es. corticosteroidi topici o sistemici, terapia ad ultravioletti – UV).
    6 Attuale uso di altri trattamenti proibiti non per la psoriasi. Devono essere rispettati i periodi di washout dettagliati nel protocollo. Tutti i trattamenti
    concomitanti precedenti per la psoriasi devono essere a dose stabile come dettagliato nel protocollo prima dell’inizio del farmaco in studio.
    7. Donne in gravidanza o allattamento, con la gravidanza definita come lo stato di una donna dopo il concepimento e fino al termine della
    gestazione, confermato da un test di laboratorio positivo per gonadotropina corionica umana (hGC) (>5 mlU/mL).
    8.Donne potenzialmente fertili, definite come tutte le donne fisiologicamente in grado di iniziare una gravidanza, a meno che non utilizzino metodi contraccettivi efficaci durante la somministrazione del farmaco in studio e per le 16 settimane successive all’interruzione del farmaco in studio.
    9.Patologie infiammatorie attive in corso diverse dalla psoriasi che potrebbero confondere la valutazione del beneficio della terapia con il
    secukinumab.
    10.Condizioni di base (comprese, ma non limitate a, condizioni metaboliche, ematologiche, renali, epatiche, polmonari, neurologiche, endocrine, cardiache, infettive o gastrointestinali) che, a giudizio dello sperimentatore, immunocompromettono il paziente in modo
    significativo e/o lo espongono ad un rischio inaccettabile nel ricevere una terapia immunomodulante.
    E.5 End points
    E.5.1Primary end point(s)
    PASI 90 response rate
    Tasso di risposta PASI 90
    E.5.1.1Timepoint(s) of evaluation of this end point
    52 weeks
    52 settimane
    E.5.2Secondary end point(s)
    Patient's assessment of pain, itching and
    scaling.
    Valutazione da parte del paziente del dolore, del prurito e della desquamazione
    E.5.2.1Timepoint(s) of evaluation of this end point
    week 52
    settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Valutazione in cieco
    Blinded-Assessment
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    secukinumab 300 mg s.c. ogni 4 settimane
    300 mg s.c. dose of secukinumab every 4 weeks
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA275
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Bulgaria
    Croatia
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Greece
    Hungary
    Ireland
    Israel
    Italy
    Latvia
    Lithuania
    Netherlands
    Norway
    Poland
    Portugal
    Romania
    Russian Federation
    Slovakia
    Spain
    Sweden
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1422
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 158
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1450
    F.4.2.2In the whole clinical trial 1580
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    When subject leaves the study the investigator will discuss the different medications or possible alternatives that are available to treat the subject's psoriasis.
    Al termine dello studio lo sperimentatore informerà il paziente dei farmaci e delle terapie disponibili per il trattamento della psoriasi.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-07-09
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 19 12:27:23 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA